ClearID is a state-of-the-art test that augments the power of genetic sequencing by molecularly characterizing tumor DNA obtained from whole blood to provide physicians with actionable information on their patients with advanced breast cancer.
Backed by years of research and development at the University of California, ClearID is uniquely able to analyze circulating tumor cells and cell free DNA from the bloodstream for genetic alterations to support evidence-based medical decisions.
The ClearID test results are described in a comprehensive report which includes the latest scientific data on the genomic mutations observed in the patient’s blood sample. The report is curated by a network of doctors and scientists and includes references to the relevant literature published in scientific journals. It also contains the latest information on how cancer mutations can be targeted by existing therapies or new drugs in development, and which active clinical trials may be suitable for the patient.
The patient sample is collected by means of a standard blood draw and then processed at Cynvenio’s lab to identify target cells that may have mutated DNA - this is called sample enrichment. Target cells originate in diseased epithelial tissue, therefore they are described as being “Cytokeratin positive”. Since they do not originate in blood they are further described as being “CD45 negative”.
Following the sample enrichment step, the target cells’ DNA is isolated and sequenced to identify cancer-associated mutations that may (or may not) be present in the blood sample.
Finally, the ClearID test results - including the nature of the DNA mutations - are documented in a comprehensive patient report. This report includes the latest data on what is known about the mutations, how they can be targeted by existing therapies or by new drugs in development with active clinical trials.
联系客服
